Beck Depression Inventory Index Research Articles

Alpha-lipoic acid administration affects psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes and coronary heart disease.

This investigation was performed to assess the effects of alpha-lipoic acid (ALA) supplementation on psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was performed in 60 patients with T2DM and CHD, aged 45-85 years. Patients were randomized into two groups to receive either 600mg/day ALA (n = 30) or placebo (n = 30) for 12 weeks. ALA supplementation significantly decreased Beck Depression Inventory index (BDI) (-5.1 ± 3.5 vs. -1.1 ± 4.8, P = 0.001) when compared with the placebo. ALA supplementation resulted also in a significant reduction of serum high sensitivity C-reactive protein (hs-CRP) (-0.8 ± 1.4 vs. +0.5 ± 0.6mg/L, P < 0.001) and malondialdehyde (MDA) (-0.3 ± 0.2 vs. -0.1 ± 0.3 µmol/L, P = 0.003), and a significant increase in plasma total antioxidant capacity (TAC) levels (+ 26.8 ± 36.0 vs. -4.6 ± 43.4 mmol/L, P = 0.007) when compared with the placebo. ALA intake upregulated transforming growth factor beta (TGF-β) (P = 0.03) and downregulated gene expression of interleukin-1 (IL-1) (P = 0.001) in peripheral blood mononuclear cells of patients with T2DM and CHD as well. ALA supplementation for 12 weeks in patients with T2DM and CHD had beneficial effects on BDI, hs-CRP, TAC, MDA values, and gene expression of IL-1 and TGF-β. The online version contains supplementary material available at 10.1007/s40200-022-01031-1.

Recovery of mental health parameters after ablation in patients with premature ventricular complex induced cardiomyopathy.

The diagnosis of premature ventricular complex-induced cardiomyopathy (PVC-CMP) is based on the presence of common PVCs associated with cardiomyopathy without a reasonable etiology for the cardiomyopathy. The treatment strategies for PVCs include radiofrequency catheter ablation (RFCA) and drug therapy. In addition to physiological symptoms, PVCs also cause psychological symptoms. Impaired quality of life and sleep quality parameters have been observed in these patients. The aim of the study was to investigate the effects of RFCA treatment on cardiac function and psychiatric health parameters. A total of 60 consecutive patients undergoing catheter ablation for cardiomyopathy-associated idiopathic PVCs were included in this study. Each patient underwent a three-lead ECG recording over a 24-hour period during normal daily ambulatory activities at a screening visit before and 3 months after RFCA. The Beck Depression Inventory Index (BDI-I), Beck Anxiety Inventory Index (BAI-I), and Global Pittsburgh Sleep Quality Index (GPSQI) were assessed before and after RFCA. PVC frequency decreased from 21.99±6.10 to 1.2% after RFCA. Left ventricular ejection fraction (LVEF) increased from 0.41±0.05 to 0.50±0.06 after RFCA (p<0.001). GPSQI (4.90±1.99 to 3.80±1.75, p <0.001), BDI-I (14.12±7.05 to 8.67±5.13, p<0.001), BAI-I (15.12±6.89 to 9.40±5.11, p<0.001) values decreased after RFCA. We found a moderate negative correlation between GPSQI, BDI-I, BAI-I and LVEF (rs=-0.56; p <0.001, rs=-0.55; p<0.001 and rs=-0.62; p<0.001). In addition to the recovery of systolic and diastolic cardiac functions, mental and psychiatric health parameters also showed great improvement.

Could emotional and sensitization status affect postural sway in adults with knee osteoarthritis?

The manipulation of sensory conditions and attentional demand affect the postural sway in older adults with knee osteoarthritis (KOA). However, it is not known if emotional and sensitization status affects postural sway in this population. This study aimed to test if older adults with mild and moderate knee osteoarthritis with symptoms of depression and high sensitization would change the profile of postural sway. Design: A cross-sectional study was undertaken. The center of pressure parameters of 30 older adults with mild and moderate knee osteoarthritis and 15 healthy controls were evaluated under different conditions manipulating the visual and attentional demand. We used the pressure pain threshold to measure the sensitization status. Furthermore, we applied the Beck Depression Inventory index to assess emotional status. Manipulating the visual demand affected the center of pressure parameters for both groups, without differences between them. Compared to the healthy control group, the knee osteoarthritis group presented with worse scores on the Beck Depression Inventory, lower pressure pain threshold scores, and the correlations between the symptoms of depression and sensitization status ranged from weak to moderate. Finally, in the knee osteoarthritis group, we observed few and weak significant associations between the center of pressure parameters and the Beck Depression Inventory and the pressure pain threshold scores. Emotional and sensitization status seem not to be more associated with the center of pressure of older adults with mild to moderate KOA than healthy adults. Thus, it suggests that this population can safely maintain postural sway, irrespective of depression symptoms and high sensitization.

The effects of combined magnesium and zinc supplementation on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease

BackgroundThe present research aimed to analyze the impacts of magnesium and zinc supplements on glycemic control, serum lipids, and biomarkers of oxidative stress and inflammation in patients suffering from coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM).MethodsAccording to the research design, a randomized, double-blind, placebo-controlled trial has been implemented on 60 subjects suffering from CHD and T2DM. Therefore, participants have been randomly divided into 2 groups for taking placebo (n = 30) or 250 mg magnesium oxide plus 150 mg zinc sulfate (n = 30) for 12 weeks.ResultsMagnesium and zinc significantly decreased fasting plasma glucose (FPG) (β − 9.44 mg/dL, 95% CI, − 18.30, − 0.57; P = 0.03) and insulin levels (β − 1.37 μIU/mL, 95% CI, − 2.57, − 0.18; P = 0.02). Moreover, HDL-cholesterol levels significantly enhanced (β 2.09 mg/dL, 95% CI, 0.05, 4.13; P = 0.04) in comparison to the placebo. There was an association between magnesium and zinc intake, and a significant decrease of C-reactive protein (CRP) (β − 0.85 mg/L, 95% CI, − 1.26, − 0.45; P < 0.001), a significant increase in total nitrite (β 5.13 μmol/L, 95% CI, 1.85, 8.41; P = 0.003) and total antioxidant capacity (TAC) (β 43.44 mmol/L, 95% CI, 3.39, 83.50; P = 0.03) when compared with placebo. Furthermore, magnesium and zinc significantly reduced the Beck Depression Inventory index (BDI) (β − 1.66; 95% CI, − 3.32, − 0.009; P = 0.04) and Beck Anxiety Inventory (BAI) (β − 1.30; 95% CI, − 2.43, − 0.16; P = 0.02) when compared with the placebo.ConclusionsIn patients with T2DM and CHD, the 12-week intake of magnesium plus zinc had beneficial effects on FPG, HDL-cholesterol, CRP, insulin, total nitrite, TAC levels, and BDI and BAI score. This suggests that magnesium and zinc co-supplementation may be beneficial for patients with T2DM and CHD. Further studies on more patients and lasting longer are needed to determine the safety of magnesium and zinc co-supplementation.Trial registrationCurrent Controlled Trials http://www.irct.ir: IRCT20130211012438N31 at 11 May 2019 of registration. This study retrospectively registered.

The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial

This study evaluated the effects of melatonin supplementation on parameters of mental health, glycemic control, markers of cardiometabolic risk, and oxidative stress in diabetic hemodialysis (HD) patients. A randomized, double-blind, placebo-controlled clinical trial was conducted in 60 diabetic HD patients, 18-80 years of age. Participants were randomly divided into 2 groups to take either melatonin (2 x 5mg/day) (n = 30) or placebo (n = 30) 1 hour before bedtime for 12 weeks. The effects of melatonin on mental health, metabolic status, and gene expression related to metabolic status were assessed using multiple linear regression adjusting for age andBMI. Melatonin supplementation significantly decreased Pittsburgh Sleep Quality Index (P=.007), Beck Depression Inventory index (P=.001), and Beck Anxiety Inventory index (P=.01) compared with the placebo. Additionally, melatonin administration significantly reduced fasting plasma glucose (β = -21.77mg/dL, 95% CI -33.22 to -10.33, P<.001), serum insulin levels (β = -1.89 μIU/mL, 95% CI -3.34 to -0.45, P=.01), and homeostasis model of assessment-insulin resistance (β = -1.45, 95% CI -2.10 to -0.80, P<.001), and significantly increased the quantitative insulin sensitivity check index (β = 0.01, 95% CI 0.007-0.02, P<.001) compared with placebo treated subjects. In addition, melatonin administration resulted in a significant reduction in serum high sensitivity C-reactive protein (β = -1.92mg/L, 95% CI -3.02 to -0.83, P=.001) and plasma malondialdehyde (β = -0.21μmol/L, 95% CI -0.36 to -0.06, P=.005); also, significant rises in plasma total antioxidant capacity (β = 253.87mmol/L, 95% CI 189.18-318.56, P<.001) and nitric oxide levels (β = 2.99μmol/L, 95% CI 0.71-5.28, P=.01) were observed compared with the placebo. Overall, melatonin supplementation for 12weeks to diabetic HD patients had beneficial effects on mental health, glycemic control, inflammatory markers, and oxidative stress.

Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

ObjectiveThe aim of this study was to evaluate the effect of melatonin supplementation on mental health parameters, metabolic and genetic parameters in women suffering from polycystic ovary syndrome (PCOS). MethodsThis randomized, double-blinded, placebo-controlled clinical trial was performed on 58 subjects, aged 18–40 years old. Subjects were randomly allocated to take either 10 mg melatonin (2 melatonin capsules, 5 mg each) (n = 29) or placebo (n = 29) once a day 1 h before bedtime for 12 weeks. Glycemic control and lipid profiles were measured at baseline and after the 12-week intervention. Using RT-PCR method, gene expression related to insulin and lipid metabolism was conducted on peripheral blood mononuclear cells (PBMCs) of PCOS women. ResultsMelatonin supplementation significantly decreased Pittsburgh Sleep Quality Index (β −2.15; 95% CI, −3.62, −0.68; P = 0.005), Beck Depression Inventory index (β −3.62; 95% CI, −5.53, −1.78; P<0.001) and Beck Anxiety Inventory index (β −1.95; 95% CI, −3.41, −0.48; P = 0.01) compared with the placebo. In addition, melatonin administration, compared with the placebo, significantly reduced serum insulin (β −1.20 µIU/mL; 95% CI, −2.14, −0.26; P = 0.01), homeostasis model of assessment-insulin resistance (HOMA-IR) (β −0.28; 95% CI, −0.50, −0.05; P = 0.01), serum total- (β −7.96 mg/dL; 95% CI, −13.75, −2.17; P = 0.008) and LDL-cholesterol levels (β −5.88 mg/dL; 95% CI, −11.42, −0.33; P = 0.03), and significantly increased the quantitative insulin sensitivity check index (QUICKI) (β 0.008; 95% CI, 0.002, 0.014; P = 0.007). Moreover, melatonin supplementation upregulated gene expression of peroxisome proliferator-activated receptor gamma (PPAR-γ) (P = 0.004) and low-density lipoprotein receptor (LDLR) (P = 0.01) compared with the placebo. ConclusionsOverall, melatonin administration for 12 weeks had beneficial effects on mental health parameters, insulin levels, HOMA-IR, QUICKI, total- and LDL-cholesterol levels, and gene expression of PPAR-γ and LDLR among women with PCOS.

The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial

The objective of this investigation was to assess the effects of probiotic and selenium co-supplementation on indicators of mental health and metabolic profiles in diabetic people with coronary heart disease (CHD). This randomized, double-blind, placebo-controlled trial was conducted among 54 diabetic people with CHD. Patients were randomly allocated into two groups to receive either 200μg/day selenium plus 8×109CFU/day probiotic (n=27) or placebo (n=27) for 12 weeks. Probiotic and selenium co-supplementation significantly decreased Beck Depression Inventory index (β-1.46; 95% CI,-2.61,-0.31; P=0.01) and Beck Anxiety Inventory index (β-1.23; 95% CI,-2.33,-0.12; P=0.02) compared with the placebo. Consuming probiotic plus selenium lowered fasting plasma glucose (β-10.80mg/dL; 95% CI,-17.68,-3.92; P=0.003), serum insulin levels (β-3.42 μIU/mL; 95% CI,-4.93,-1.90; P<0.001), insulin resistance (β-0.96; 95% CI,-1.45,-0.47; P<0.001), and enhanced insulin sensitivity (β 0.01; 95% CI, 0.007, 0.01; P<0.001) compared with the placebo. Additionally, co-supplementation reduced triglycerides (β-34.45mg/dL; 95% CI,-56.18,-12.72; P=0.003), VLDL- (β-6.89mg/dL; 95% CI,-11.23,-2.54; P=0.003), total cholesterol (β-18.13mg/dL; 95% CI,-23.42,-2.83; P=0.02) and high sensitivity C-reactive protein (β-1043.28ng/mL; 95% CI,-1929.67,-156.89; P=0.02), and increased nitric oxide (β 7.86μmol/L; 95% CI, 5.63, 10.09; P<0.001), total antioxidant capacity (β 119.30mmol/L; 95% CI, 63.04, 175.57; P<0.001) and total glutathione (β 154.16μmol/L; 95% CI, 82.57, 225.74; P<0.001) compared with the placebo. Probiotic and selenium co-supplementation to diabetic people with CHD improved indicators of mental health and metabolic profiles. Registered under Clinical Trials.gov Identifier no. http://www.irct.ir: IRCT20170513033941N28.

The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.

This investigation was designed to determine the effect of melatonin supplementation on mental health parameters, metabolic and genetic profiles in patients under methadone maintenance treatment (MMT). This randomized, double-blind, placebo-controlled, clinical trial was conducted among 54 patients under MMT. Participants were randomly allocated to receive either 10mg melatonin (2 melatonin capsules, 5mg each) (n=26) or placebo (n=28) once a day, 1hour before bedtime for 12weeks. Melatonin supplementation significantly decreased Pittsburgh Sleep Quality Index (β -4.08; 95 percent CI, -5.51, -2.65; P<0.001), Beck Depression Inventory index (β -5.46; 95% CI, -8.92, -2.00; P=0.003) and Beck Anxiety Inventory index (β -3.87; 95% CI, -5.96, -1.77; P=0.001) and significantly increased International Index of Erectile Functions (β 5.59; 95% CI, 1.76, 9.42; P=0.005) compared with the placebo. Subjects who received melatonin supplements had significantly lower serum insulin levels (β -2.53; 95% CI, -4.48, -0.59; P=0.01), homeostasis model of assessment-insulin resistance (β -0.56; 95% CI, -1.03, -0.09; P=0.01) and higher quantitative insulin sensitivity check index (β 0.01; 95% CI, 0.004, 0.02; P=0.009) and HDL-cholesterol levels (β 3.71; 95% CI, 1.77, 5.64; P=0.002) compared to placebo. Additionally, melatonin intake resulted in a significant reduction in serum high sensitivity C-reactive protein (β -0.15; 95% CI, -0.27, -0.02; P=0.02), malondialdehyde (β -0.31; 95% CI, -0.57, -0.05; P=0.02) and protein carbonyl (β -0.06; 95% CI, -0.09, -0.04; P<0.001). This trial indicated that taking melatonin supplements for 12weeks by patients under MMT had beneficial effects on their mental health metabolic profiles.

Heart rate variability in patients with major depressive disorder and healthy controls during non-REM sleep and REM sleep.

The objectives of this study are to investigate heart rate variability (HRV) in major depressive disorder patients (MDD) and healthy controls during different sleep stages, and to examine the association of HRV during sleep and depression severity. Polysomnography was recorded from 15 depressive patients with a higher beck depression inventory index (BDI > 25, H-BDI-D), 15 depressive patients with a lower BDI index (BDI ≤ 25, L-BDI-D) and 15 healthy controls. HRV was calculated during the first three rapid eye movements (REM) periods and non-REM stages (i.e. sleep stage 2 and 3) with time domain, power spectral and fractal analysis. As a result, H-BDI-D patients showed the highest short-term fractal alpha-1 exponent during first REM period and healthy controls had the lowest values. Our results suggest an association between the depression severity and the autonomic nerve function, especially during the first REM sleep. The pathophysiological analysis for this property should be conducted in future prospective studies.

Usefulness of the organ culture system when villous height/crypt depth ratio, intraepithelial lymphocyte count, or serum antibody tests are not diagnostic for celiac disease

The existence of mild forms of celiac disease (CD) can make the histology-based diagnosis difficult to reach. Since anti-endomysium (EMA) and anti-tissue transglutaminase (anti-tTG) are detectable in culture supernatants of duodenal biopsies from CD patients, our aim was to assess if this system can support the histology in the diagnostic work-up. A total of 559 suspected CD patients underwent serum EMA/anti-tTG detection, upper endoscopy with duodenal biopsy sampling, histologic analysis, and organ culture to detect EMA/anti-tTG in supernatants. A subgroup of 30 patients with organ culture positive results were put on a gluten-free diet (GFD). Their gluten-dependency was evaluated by the psychological general well-being and beck depression inventory indexes. Statistical analysis was performed by Cohen k inter-test, Friedman test, and Dunn multiple comparison. Two hundred forty-one out of 559 (43.1%) patients showed intestinal villous atrophy, whereas serum and organ culture EMA/anti-tTG were positive in 293/559 (52.4%) and 334/559 (59.7%) patients, respectively. The strength of agreement resulted good for serology vs histology (k = 0.730), good for organ culture vs histology (k = 0.662), and very good for serology vs organ culture (k = 0.852). After 12 months of GFD, psychological general well-being index significantly increased, and beck depression inventory index significantly decreased (P < 0.001 for each one). Data highlight the organ culture system as a useful tool to assist the histology in diagnosing CD, mainly in cases without villous atrophy or in seronegative patients. The marked improvement in quality of life after a GFD further supports the reliability of this system in diagnosing CD.

Causal factors in spinal cord injury: Patients' evolving perceptions and association with depression

Do spinal cord injured patients who accept responsibility for their injury cope better than those who blame others? Previous investigations have yielded conflicting answers to this question. On the assumption that some portion of the disparity in earlier findings derives from the failure of early investigators to conceptualize "blame" as a dynamic phenomenon, the present study approached the question via a longitudinal study. Specifically, we examined: (1) the evolution of patients' perceptions of responsibility for spinal cord injury, and (2) the changing association of this factor with depression over a 2-year period, beginning with inpatient rehabilitation. Eighteen men with traumatic spinal cord injury were evaluated during acute rehabilitation and again at 18 to 24 months following discharge. Patients assigned proportions of blame for their injury to four possible causal factors (self, environment, chance, others). Three indices of depression were derived from the Beck Depression Inventory (BDI). Eighty-nine percent of the subjects displayed shifts in pattern of blame assignment between initial and follow-up evaluations. Individuals whose self-blame score increased over time exhibited increased depression, as did those who came to attribute to "chance" lesser blame for their injury. During inpatient rehabilitation, no aspect of blame correlated significantly with any of the three BDI indices, although "other blame" and the cognitive/affective BDI index just failed to reach conventional levels (r = .43, p = .07). By contrast, at follow-up evaluation, "self blame" was positively correlated with both the cognitive/affective (r = .51, p = .03) and Total (r = .46, p = .05) BDI scores. All other correlations were not statistically meaningful.(ABSTRACT TRUNCATED AT 250 WORDS)